https://orcid.org/0000-0003-0244-3457
Figures
Abstract
To minimize the intrinsic toxicity of the antibacterial agent hydrazinyloxadiazole 1, the hydrazine moiety was replaced with ethylenediamine (compound 7). This replacement generated a potent antifungal agent with no antibacterial activity. Notably, use of a 1,2-diaminocyclohexane moiety, as a conformationally-restricted isostere for ethylenediamine, potentiated the antifungal activity in both the cis and trans forms of N-(5-(2-([1,1’-biphenyl]-4-yl)-4-methylthiazol-5-yl)-1,3,4-oxadiazol-2-yl)cyclohexane-1,2-diamine (compounds 16 and 17). Both compounds 16 and 17 were void of any antibacterial activity; nonetheless, they showed equipotent antifungal activity in vitro to that of the most potent approved antifungal agent, amphotericin B. The promising antifungal effects of compounds 16 and 17 were maintained when assessed against an additional panel of 26 yeast and mold clinical isolates, including the Candida auris and C. krusei. Furthermore, compound 17 showed superior activity to amphotericin B in vitro against Candida glabrata and Cryptococcus gattii. Additionally, neither compound inhibited the normal human microbiota, and both possessed excellent safety profiles and were 16 times more tolerable than amphotericin B.
Citation: Hagras M, Abutaleb NS, Sayed AM, Salama EA, Seleem MN, Mayhoub AS (2021) Evaluation of bisphenylthiazoles as a promising class for combating multidrug-resistant fungal infections. PLoS ONE 16(11): e0258465. https://doi.org/10.1371/journal.pone.0258465
Editor: Haroon Mohammad, UNITED STATES
Received: October 13, 2020; Accepted: September 28, 2021; Published: November 4, 2021
Copyright: © 2021 Hagras et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting information files.
Funding: This paper is based upon work supported by Science, Technology & Innovation Funding Authority (STDF) under grant number 43883.
Competing interests: The authors have declared that no competing interests exist.
Abbreviations: MFC, minimum fungicidal concentration; MIC, minimum inhibitory concentration; NAC, non-albicans Candida species
1. Introduction
More than 1.6 million patients die annually as a result of fungal infections. This crisis has positioned fungi at the same level of threat as tuberculosis, and the threat is 3-fold more serious than that of malaria [1]. Candida, Aspergillus, and Cryptococcus are the principal fungal pathogens responsible for human morbidity and mortality [2]. Clinical management of Candida infections is highly compromised by the increasing resistance to the current antifungal agents, such as fluconazole [3]. Further compounding the problem is the increasing incidence of infected patients with an immunodeficient status. Consequently, the mortality rate of candidemia currently ranges between 36% and 63% [3–5]. Recently, the isolation of panazole-resistant strains of Aspergillus fumigatus has been reported at an increasing frequency, thereby complicating disease management. Furthermore, cryptococcal meningitis is responsible for more than 180,000 deaths annually [6]. Its treatment options are limited due to the increased resistance and inadequacy of the current antifungal therapeutics [7]. Thus, the low number of available antifungals and the increasing resistance to them require the development of new classes of effective antifungals.
During the last five years, our group has optimized polysubstituted phenylthiazoles as a new class of antibacterial agents [8–10]. Our synthesized compounds were screened intuitively against bacterial and fungal species to assess their antimicrobial activity prior to further investigation. Through continuous modification, we discovered that the hydrazinyl cationic side chain provided the phenylthiazole core with potency against multidrug-resistant staphylococcal infections [11] (Fig 1). Unfortunately, activation of hydrazine inside the body is presumed to generate aryl free radicals, which results in serious oxidative stress and induces acute liver injury in the case of isoniazid and iproniazid (the two known hydrazine-containing antitubercular therapeutics with black-box warnings) [12–15]. To prevent the endogenous activation of hydrazine, we performed further derivatization by inserting methylene units between the two pharmacophoric nitrogen atoms to form ethylenediamine derivatives (1st compound in Table 1). Interestingly, we found that this derivative exhibited dual antibacterial and antifungal activity (Fig 1), and we hypothesized that this mixed activity is due to the free rotation of the terminal nitrogen around the formed ethylene moiety.
In the present work, we aimed to maximize the antifungal potency of bisphenylthiazoles by studying the structure-activity relationships (SAR) at oxadiazole position-2. In this regard, several bio-isosteres to the ethylenediamine moiety were utilized with a specific focus on cyclic alternatives and the stereochemistry of the two amines.
2. Results and discussion
2.1. Chemistry
Methylsulfone, as a good leaving group, was used to access nucleophilic aromatic substitution on the oxadiazole ring. Compound 6 was prepared as previously reported [11], starting from the acid hydrazine (compound 4), and then the compound allowed to react with various amine-containing synthons to yield the desired final products, compounds 7–21 (Scheme 1).
Scheme 1. Reagents and conditions: (a) Absolute EtOH, ethyl 2-chloroacetoacetate, heat at reflux, 4 h, (b) Absolute EtOH, NH2NH2 H2O, heat at reflux, 8 h; (c) CS2, KOH, EtOH, heat at reflux, 12 h; (d) dimethyl sulfate, KOH, H2O, stirring at 23 °C, 2 h; (e) MCPBA, dry DCM, 23 °C, 16 h; (f) appropriate amine; K2CO3, DMF, heat at 80 °C for 0.5–12 h.
The stereochemistry of the final products was derived from their corresponding starting materials because a one-step substitution reaction was not expected to affect the spatial configuration of the final compounds. Of note, the chemical structures of compounds 10 and 15 were found to be joined by an oxadiazole ring via the pyrrolidine/piperidine nitrogen rather than the terminal primary amine-based on their spectral data. In brief, all diaminocyclohexane-containing compounds (16–18) displayed two broad deuterium-exchangeable signals, with one within the aromatic region between 6.7 and 7.9 ppm, which was equivalent to one proton. However, a signal that was equivalent to two protons was displayed in the upper field region at approximately δ 1.6. Therefore, the presence of only one broad signal, which was equivalent to two deuterium-exchangeable protons, in the cases of compounds 10 and 15, indicates that the pyrrolidine and piperidine NH groups replaced the methylsulfonyl moiety of compound 6, which confirms the proposed chemical structures of the final products (10 and 15).
2.2. Biological results and discussion
2.2.1. Initial antimicrobial SAR.
Our synthesized compounds were tested against two Gram-positive bacteria (MRSA and Clostridioides difficile), two Gram-negative bacterial strains (Escherichia coli tolC-mutant and wild-type), and a fungal species (Candida albicans). The ethylenediamine-containing derivative 7 showed moderate antifungal activity against C. albicans (MIC = 4 μg/mL) and weak antibacterial activity against the tested bacterial strains.
Because we anticipate that the high flexibility of the free-rotating ethylenediamine motif is responsible for the dual antibacterial/antifungal activities of compound 7, we hypothesized that the antifungal effect would be enhanced when the spatial arrangement matched the bioactive form. Consequently, we synthesized a small set of conformationally-restricted analogs. In this regard, the cyclohexyl moiety with 1,2-diamine provided the most potent derivatives (compounds 16 and 17). Both compounds were equipotent to amphotericin B against the tested strain (MIC = 1 μg/mL). The 1,4-diaminocyclohexane derivative (compound 18) was prepared with the objective of testing the effect of increasing the carbon chain length between the two amines on the antimycotic activity. The MIC results revealed that increasing the number of carbons between the two amines had a negative impact on the antifungal activity, suggesting that a distance of two carbon units is optimal for the activity. However, all pyrrolidine-containing derivatives (10–14) were less active than the lead compound (7) (Table 1).
Next, we determined whether the hydroxyl group can act as a bio-isostere to the terminal amine. The high MIC values of the hydroxylated derivatives (19–21) against all tested microbes confirmed the importance of the terminal primary amine for the antimicrobial activity. Dimethylation (compound 8) or replacement with an imidine group (compound 9) significantly reduced the antimycotic activity.
Next, we were interested to investigate the anticommensal activity of our prioritized compounds (7, 16 and 17). The human body contains a large number of beneficial microorganisms, which play a significant role in combating pathogens, provide essential elements to the host cells and facilitate the functionality of the host immune system [16]. The ideal antifungal therapeutic should not affect these important roles of the normal microbiota. Therefore, our most promising compounds 7, 16 and 17 were tested against different normal human microbiota strains including Lactobacillus gasseri, L. casei, and L. crispatus. The compounds did not inhibit the tested normal human microbiota strains (Table 2).
2.2.1.1. Profiling of antifungal activity. We next moved to expand the antifungal assessment using a large panel of clinically important fungal strains. In general, compounds 7, 16 and 17 exhibited a broad spectrum of activity against all the tested Candida and Cryptococcus isolates.
Compounds 16 and 17 exhibited potent activity against C. albicans, inhibiting the growth of tested strains at concentrations ranging from 2 to 4 μg/mL (Table 3). Additionally, these compounds maintained the same activity against the fluconazole-resistant C. albicans strain NR-29448. New compounds, capable of exhibiting potent activity against fluconazole-resistant C. albicans strains, are highly desirable because overcoming C. albicans infections is more difficult due to the increasing resistance to azoles, specifically fluconazole [17].
Moreover, the bisphenylthiazole activity was extended to include other non-albicans Candida (NAC) species such as C. glabrata, C. parapsilosis, C. tropicalis and C. krusei with MICs ranging from 0.5 to 4 μg/ mL (Table 3). The MICs of compounds 16 and 17 were 2–4 folds lower than that of amphotericin B and 8 to 16 folds lower than that of fluconazole, when tested against two C. glabrata strains. Caspofungin inhibited the tested C. glabrata strains at concentrations ranging from 0.125 μg/mL to 0.25 μg/mL. C. glabrata is the most common NAC and is isolated from vulvovaginal candidiasis and candiduria [18]. As a causative agent of superficial or systemic candidal infections, C. glabrata is ranked second or third according to the geographical distribution [19, 20]. In the United States, Europe, and Australia, C. glabrata was reported to be the second most common cause of vulvovaginal candidiasis after C. albicans [21]. Additionally, it has been reported that approximately 3% of C. glabrata isolates are resistant to echinocandins, the first-line treatment for this pathogen, and have high levels of resistance to azoles, that further complicates the treatment of C. glabrata infections [22].
Additionally, C. krusei was susceptible to both diaminocyclohexane derivatives (compounds 16 and 17); these compounds were one-fold more potent than the drug of choice (amphotericin B) in such cases and several times more potent than the most commonly prescribed antifungal drug (fluconazole). Currently, C. krusei is common in patients with hematological malignancies and causes invasive candidiasis. In addition, approximately 2.7% of NAC isolated cases belong to this strain [23, 24]. Most C. krusei isolates are intrinsically resistant to azoles [24]. Furthermore, compounds 16 and 17 exhibited potent activity against other tested NAC species such as C. parapsilosis and C. tropicalis, with MICs ranging from 1 to 4 μg/mL.
The newly synthesized compounds showed promise in controlling cryptococcal infections, which are responsible for hundreds of thousands of deaths annually [6]. Our most potent compounds inhibited the tested strains at concentrations as low as 0.5–1 μg/mL. They were equipotent to the drug of choice, amphotericin B.
Among all Candida infections, C. auris is of particular clinical concern because this particular species has emerged as a highly resistant fungal pathogen that has been isolated on five continents [25]. Despite implementing strict infection prevention and control measures, C. auris is associated with numerous nosocomial outbreaks worldwide [26, 27]. Additionally, C. auris showed an enhanced resistance profile to most antifungal agents, especially to first-line treatment with oral fluconazole, making C. auris infections one of the most difficult fungal infections to treat. Up to 93% of C. auris isolates have been reported to be fluconazole-resistant [28]. Unfortunately, fluconazole treatment failure has been reported for fluconazole-sensitive isolates in the USA [29]. Additionally, reduced susceptibility to other antifungals such as voriconazole, itraconazole, and isavuconazole, has been reported [30–32]. Moreover, some isolates were reported to be amphotericin B-resistant. Hence, the great need for novel broad-spectrum antifungal compounds cannot be overemphasized. Therefore, we screened our most promising compounds against ten C. auris strains. Interestingly, compounds 16 and 17 displayed potent activity against all C. auris strains, including fluconazole-resistant strains, inhibiting their growth, with MIC values ranging from 1 to 2 μg/mL (Table 4). The antifungal activity of both bisphenylthiazole compounds against C. auris strains was similar to that of the standard antifungal agent amphotericin B. Conversely, the lead compound 7 exhibited moderate activity against all tested C. auris strains with MIC values ranging from 2 to 8 μg/mL.
Next, we investigated whether the activity of bisphenylthiazoles could be expanded against molds. Compounds 16 and 17 exhibited reasonable activity against Aspergillus fumigatus, with MIC values of 4 μg/mL, which exceeded the activity of the lead compound (7) (Table 5). Due to the inadequacy of the current antifungals and the increased resistance of Aspergillus to the available drugs, the mortality rate of aspergillosis exceeds 88% [33].
2.2.2. The fungistatic activity of compound 17.
After confirming the broad spectrum of activity of bisphenylthiazoles against fungal strains, we explored their mode of inducing cell death. The minimum fungicidal concentration of the most potent compound (compound 17) was determined against several Candida strains including C. albicans, C. auris, C. glabrata, C. tropicalis and C. krusei. The compound showed fungistatic activity against the strains tested (Table 6). Fluconazole exhibited a fungistatic activity while amphotericin B exhibited a fungicidal effect with MFC values ranging from 1 to 2 μg/mL.
2.2.3. Toxicity profile for bisphenylthiazole compounds.
Mammalian toxicity is the main obstacle that prevents the development of new antifungal drugs due to the similarity between fungal and human cells as they are both eukaryotic cells. The currently available antifungals still have great toxicity in clinical applications [34]. For instance, the azoles are limited by their hepatotoxicity, which has resulted in discontinuation of therapy in some patients. Additionally, amphotericin B is associated with a major side effect, nephrotoxicity, which limits its use [35]. Consequently, the preliminary safety profiles of the top three bisphenylthiazole candidates, compounds 7, 16 and 17, were assessed using two mammalian cell lines. In general, the three tested compounds (7, 16 and 17) were found to be non-toxic to Caco-2 and Vero cells at concentrations as high as 64 μg/mL, as shown by their 50% cytotoxic concentration (CC50), which is the concentration of the compound that leads to 50% viability of the treated cells (Fig 2). Interestingly, regardless of the high matching between the cis- and trans-diaminocyclohexyl derivatives of compounds 16 and 17 in their MIC values, the trans analog exhibited better tolerability by Caco-2 cells because its CC50 exceeded the limit of 128 μg/mL (Fig 2). In all cases, all tested compounds (7, 16 and 17) were obviously less toxic than amphotericin B, which exhibited toxicity in Vero cells at a very low concentration (8 μg/mL), (S1 Fig) in agreement with previous reports [36–38].
The data represent the percentage of viable Caco-2 or Vero cells measured as the average absorbance relative to DMSO after exposure to the tested compounds. Dimethyl sulfoxide (DMSO) was used as a negative control. Error bars represent the standard deviation values.
2.2.4. Antifungal synergy measurement by checkerboard testing.
Combination therapy has become a standard for several diseases. This strategy is currently often used in the healthcare setting to exploit the advantages of drugs combinations such as different mechanisms of action, lower toxicity, potential synergism and less probability of development of resistance to both agents [39, 40]. Given the increasing morbidity and mortality associated with invasive fungal infections, treatment with a combination of antifungal agents is often considered [41]. We investigated the interactions between compound 17 and the conventional antifungal drugs using a checkerboard assay. As presented in Fig 3, compound 17 displayed an additive relationship when combined with either fluconazole, 5-fluorocytosine or caspofungin against the two tested C. auris isolates with a FICI ranging from 1.001 to 1.25 (S1 File). Since the treatment course of most invasive fungal infections is long, combination therapy is highly desirable to decrease the probability of developing resistance and the toxicity of the administered antifungals.
A checkerboard assay was performed and bacterial growth (OD600), relative to the negative control, was measured using a spectrophotometer.
3. Conclusion
We examined the SAR at the oxadiazole-C2 and introduced two antifungal bisphenylthiazoles (compounds 16 and 17) with optimized action and improved properties. Both compounds exhibited potent fungistatic activity against a panel of clinically-relevant fungal isolates including multi-drug resistant C. auris. Furthermore, their toxicity profile was better than that of amphotericin B. The active compounds developed in this study were selective for fungal cells without disrupting the representative normal human microbiota. Moreover, these compounds acted additively with the standard antifungal agents.
4. Materials and methods
4.1. General chemistry
The purity of all biologically-tested compounds was confirmed to be at least 95% using elemental analysis. All starting material chemicals and solvents were obtained from commercial sources. The masses were weighed on a microbalance with a resolution of 0.0001 g. Visualization on TLC was performed using UV light (254 nm). 1H NMR spectra were run at 400 MHz, and 13C spectra were determined at 100 MHz in deuterated dimethyl sulfoxide (DMSO-d6) on a Varian Mercury VX-400 NMR spectrometer. Chemical shifts are given in parts per million (ppm) on the delta (δ) scale. Chemical shifts were calibrated relative to those of the solvents. Flash chromatography was performed on 230–400 mesh silica. The progress of reactions was monitored with Merck silica gel IB2-F plates (0.25 mm thickness). Mass spectra were recorded at 70 eV. High-resolution mass spectra for all ionization techniques were obtained from a FinniganMAT XL95. Melting points were determined using capillary tubes with a Stuart SMP30 apparatus and are uncorrected. Microanalyses for C, H and N were performed at the Regional Center for Mycology and Biotechnology, Al-Azhar University. All yields reported referring to isolated yields. Compounds 3–6 were prepared as reported elsewhere [42].
4.1.1. Compounds 7–21.
4.1.1.1. General procedure. The methylsulfone 6 (0.1 g, 0.26 mmol) was stirred in dry DMF (5 mL) to complete dissolution, and then a proper alkylamine (0.4 mmol), used as obtained for the commercial source, was added. The reaction mixtures were flushed with dry nitrogen and heated to 80 °C. The progress of the reaction was monitored by TLC. After consuming all starting materials in a period ranging from 0.5 to 12 h, the reaction mixture was allowed to cool to room temperature and quenched with ice water (50 mL). The formed solids were filtered, washed with 50% ethanol and purified by crystallization from absolute ethanol to yield the desired products. The yields, physical properties and spectral analyses of isolated products are listed below:
4.1.2. N-{5-[2-((1,1’-Biphenyl)-4-yl)-4-methylthiazol-5-yl]-1,3,4-oxadiazol-2-yl}ethane-1,2-diamine (7).
Following the general procedure, and using ethylenediamine (21 μL, 0.4 mmol), compound 7 was obtained as yellow solid (0.06 g, 66%) mp = 145–146 °C; 1H NMR (DMSO-d6) δ: 8.06 (d, J = 8.4 Hz, 2H), 7.93 (brs, 1H), 7.81 (d, J = 8.4 Hz, 2H), 7.71 (d, J = 7.2 Hz, 2H), 7.48 (t, J = 7.6 Hz, 2H), 7.38 (t, J = 6.8 Hz, 1H), 3.57–3.53 (m, 2H), 2.65 (s, 3H), 2.63–2.58 (m, 2H), 1.20 (brs, 2H); MS (m/z) 377; HRMS (EI) m/z 377.1310 M+, calcd for C20H19N5OS 377.1310; Anal. Calc. for: (C20H19N5OS): C, 63.64; H, 5.07; N, 18.55%; Found: C, 63.64; H, 5.07; N, 18.55%.
4.1.3. N-{5-[2-((1,1’-Biphenyl)-4-yl)-4-methylthiazol-5-yl]-1,3,4-oxadiazol-2-yl}-N,N-dimethylethane-1,2-diamine (8).
Following the general procedure, and using N,N-dimethylenediamine (35 μL, 0.4 mmol), compound 8 was obtained as yellow solid (0.1 g, 98%) mp = 98 °C; 1H NMR (DMSO-d6) δ: 8.03 (d, J = 8.4 Hz, 2H), 7.80 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.42 (t, J = 6.8 Hz, 1H), 6.93 (brs, 1H), 3.42–3.39 (m, 2H), 2.69 (s, 3H), 2.44–2.38 (m, 2H), 2.18 (s, 6H); MS (m/z) 405; HRMS (EI) m/z 405.1623 M+, calcd for C22H23N5OS 405.1623; Anal. Calc. for: (C22H23N5OS): C, 65.16; H, 5.72; N, 17.27%; Found: C, 65.16; H, 5.72; N, 17.27%.
4.1.4. 2-{[5-(2-((1,1’-biphenyl)-4-yl)-4-methylthiazol-5-yl)-1,3,4-oxadiazol-2-yl]amino} acetimidamide (9).
Following the general procedure, using 2-aminoacetimidamide dihydrobromide (93 mg, 0.4 mmol) and potassium carbonate anhydrous (0.1 g, 0.7 mmol), compound 9 was obtained as brown solid (0.06 g, 58%) mp = 292–294 °C; 1H NMR (DMSO-d6) δ: 1H NMR (DMSO-d6) δ: 8.06 (d, J = 8.4 Hz, 2H), 7.96 (brs, 2H), 7.85 (d, J = 8.4 Hz, 2H), 7.73 (d, J = 7.2 Hz, 2H), 7.53 (t, J = 7.6 Hz, 2H), 7.43 (t, J = 6.8 Hz, 1H), 6.68 (brs, 1H), 3.83 (s, 2H), 2.68 (s, 3H); MS (m/z) 390; HRMS (EI) m/z 390.1263 M+, calcd for C20H18N6OS 390.1263; Anal. Calc. for: (C20H18N6OS): C, 61.52; H, 4.65; N, 21.52%; Found: C, 61.52; H, 4.65; N, 21.52%.
4.1.5. 5-{2-[(1,1’-Biphenyl)-4-yl]-4-methylthiazol-5-yl}-N-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2-amine (10).
Following the general procedure, using 3-amino-pyrrolidine dihydrochloride (60 mg, 0.4 mmol) and potassium carbonate anhydrous (0.1 g, 0.7 mmol), compound 10 was obtained as yellow solid (0.07 g, 76%) mp = 116–117 °C; 1H NMR (DMSO-d6) δ: 8.05 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.42 (t, J = 6.8 Hz, 1H), 3.63–3.51 (m, 3H), 2.72 (s, 3H), 2.07–2.05 (m, 2H), 1.77–1.76 (m, 2H), 1.21 (brs, 2H); MS (m/z) 403; HRMS (EI) m/z 403.1467 M+, calcd for C22H21N5OS 403.1467; Anal. Calc. for: (C22H21N5OS): C, 65.49; H, 5.25; N, 17.36%; Found: C, 65.49; H, 5.25; N, 17.36%.
4.1.6. (R)-1-{5-[2-((1,1’-biphenyl)-4-yl)-4-methylthiazol-5-yl]-1,3,4-oxadiazol-2-yl}-N,N-dimethylpyrrolidin-3-amine (11).
Following the general procedure, and using ((R)-(+)-3-(dimethylamino)pyrrolidine dihydrochloride (74 mg, 0.4 mmol) and potassium carbonate anhydrous (0.1 g, 0.7 mmol), compound 11 was obtained as yellow solid (0.08 g, 79%) mp = 165–167 °C; 1H NMR (DMSO-d6) δ: 8.06 (d, J = 8.4 Hz, 2H), 7.83 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.42 (t, J = 6.8 Hz, 1H), 3.68–3.65 (m, 3H), 3.50–3.48 (m, 2H), 2.87–2.84 (m, 1H), 2.70 (s, 3H), 2.18 (s, 6H), 1.87–1.85 (m, 1H); MS (m/z) 431; HRMS (EI) m/z 431.1780 M+, calcd for C24H25N5OS 431.1780; Anal. Calc. for: (C24H25N5OS): C, 66.80; H, 5.84; N, 16.23%; Found: C, 66.80; H, 5.84; N, 16.23%.
4.1.7. (S)-1-{5-[2-((1,1’-biphenyl)-4-yl)-4-methylthiazol-5-yl]-1,3,4-oxadiazol-2-yl}-N,N-dimethylpyrrolidin-3-amine (12).
Following the general procedure, and using (S)-(-)-3-(dimethylamino)pyrrolidine (45 μL, 0.4 mmol), compound 12 was obtained as yellow solid (0.06 g, 61%) mp = 185–187 °C; 1H NMR (DMSO-d6) δ: 8.05 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.40 (t, J = 6.8 Hz, 1H), 3.67–3.60 (m, 3H), 3.51–3.44 (m, 2H), 2.86–2.83 (m, 1H), 2.69 (s, 3H), 2.18 (s, 6H), 1.85–1.80 (m, 1H); MS (m/z) 431; HRMS (EI) m/z 431.1780 M+, calcd for C24H25N5OS 431.1780; Anal. Calc. for: (C24H25N5OS): C, 66.80; H, 5.84; N, 16.23%; Found: C, 66.80; H, 5.84; N, 16.23%.
4.1.8. (S)-1-{5-[2-((1,1’-biphenyl)-4-yl)-4-methylthiazol-5-yl]-1,3,4-oxadiazol-2-yl}pyro-lidine-2-carboxamide (13).
Following the general procedure, and using L-prolinamide (45 mg, 0.4 mmol), compound 13 was obtained as yellow solid (0.08 g, 77%) mp = 115–116 °C; 1H NMR (DMSO-d6) δ: 8.06 (d, J = 8.4 Hz, 2H), 7.83 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.40 (t, J = 6.8 Hz, 1H), 7.16 (brs, 2H), 4.29–4.23 (m, 1H), 3.63–3.56 (m, 2H), 2.65 (s, 3H), 2.27–2.25 (m, 1H), 1.96–1.93 (m, 3H); MS (m/z) 431; HRMS (EI) m/z 431.1416 M+, calcd for C23H21N5O2S 431.1416; Anal. Calc. for: (C23H21N5O2S): C, 64.02; H, 4.91; N, 16.23%; Found: C, 64.02; H, 4.91; N, 16.23%.
4.1.9. (R)-1-{5-[2-((1,1’-biphenyl)-4-yl)-4-methylthiazol-5-yl]-1,3,4-oxadiazol-2-yl}pyro-lidine-2-carboxamide (14).
Following the general procedure, and using D-prolinamide (45 mg, 0.4 mmol), compound 14 was obtained as yellow solid (0.08 g, 79%) mp = 119–120 °C; 1H NMR (DMSO-d6) δ:8.05 (d, J = 8.4 Hz, 2H), 7.83 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.47 (t, J = 6.8 Hz, 1H), 7.16 (brs, 2H), 4.29–4.27 (m, 1H), 3.63–3.53 (m, 2H), 2.67 (s, 3H), 2.29–2.25 (m, 1H), 1.97–1.93 (m, 3H); MS (m/z) 431; HRMS (EI) m/z 431.1416 M+, calcd for C23H21N5O2S 431.1416; Anal. Calc. for: (C23H21N5O2S): C, 64.02; H, 4.91; N, 16.23%; Found: C, 64.02; H, 4.91; N, 16.23%.
4.1.10. {1-[5-(2-((1,1’-Biphenyl)-4-yl)-4-methylthiazol-5-yl)-1,3,4-oxadiazol-2-yl]piperidin-2-yl}methanamine (15).
Following the general procedure, and using 2-(aminomethyl)piperidine (45 μL, 0.4 mmol), compound 15 was obtained as yellow solid (0.06 g, 59%) mp = 225–227 °C; 1H NMR (DMSO-d6) δ: 8.05 (d, J = 8.4 Hz, 2H), 7.83 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.42 (t, J = 6.8 Hz, 1H), 3.85–3.82 (m, 1H), 3.15–3.13 (m, 2H), 2.69 (s, 3H), 1.73–1.49 (m, 7H), 1.29 (brs, 2H), 1.08–1.03 (m, 1H); MS (m/z) 431; HRMS (EI) m/z 431.1780 M+, calcd for C24H25N5OS 431.1780; Anal. Calc. for: (C24H25N5OS): C, 66.80; H, 5.84; N, 16.23%; Found: C, 66.80; H, 5.84; N, 16.23%.
4.1.11. N-{5-[2-((1,1’-Biphenyl)-4-yl)-4-methylthiazol-5-yl]-1,3,4-oxadiazol-2-yl}cyclo-hexane-trans-1,2-diamine (16).
Following the general procedure, and using (±)-trans-1,2-diaminocyclohexane (45 μL, 0.4 mmol), compound 16 was obtained as orange solid (0.08 g, 82%) mp = 180–183 °C; 1H NMR (DMSO-d6) δ: 7.98 (d, J = 8.4 Hz, 2H), 7.81 (d, J = 8.4 Hz, 2H), 7.73 (d, J = 7.2 Hz, 2H), 7.48 (t, J = 7.6 Hz, 2H), 7.42 (t, J = 6.8 Hz, 1H), 6.71 (brs, 1H), 3.85–3.83 (m, 2H), 2.70 (s, 3H), 2.10–1.99 (m, 2H), 1.88 (brs, 2H), 1.72–1.64 (m, 2H), 1.30–1.23 (m, 4H); MS (m/z) 431; HRMS (EI) m/z 431.1780 M+, calcd for C24H25N5OS 431.1780; Anal. Calc. for: (C24H25N5OS): C, 66.80; H, 5.84; N, 16.23%; Found: C, 66.80; H, 5.84; N, 16.23%.
4.1.12. cis-N-{5-[2-((1,1’-Biphenyl)-4-yl)-4-methylthiazol-5-yl]-1,3,4-oxadiazol-2-yl}cyclo-hexane-1,2-diamine (17).
Following the general procedure, and using (±)-cis-1,2-diaminocyclohexane (45 μL, 0.4 mmol), compound 17 was obtained as brown solid (0.08 g, 85%) mp = 145–146 °C; 1H NMR (DMSO-d6) δ: 7.95 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 8.4 Hz, 2H), 7.72 (d, J = 7.2 Hz, 2H), 7.47 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 6.8 Hz, 1H), 7.03 (brs, 1H), 3.74–3.72 (m, 2H), 2.87–2.85 (m, 2H), 2.68 (s, 3H), 1.80–1.69 (m, 2H), 1.44 (brs, 2H), 1.26–1.20 (m, 4H); MS (m/z) 431; HRMS (EI) m/z 431.1780 M+, calcd for C24H25N5OS 431.1780; Anal. Calc. for: (C24H25N5OS): C, 66.80; H, 5.84; N, 16.23%; Found: C, 66.80; H, 5.84; N, 16.23%.
4.1.13. trans-N-{5-[2-((1,1’-Biphenyl)-4-yl)-4-methylthiazol-5-yl]-1,3,4-oxadiazol-2-yl}cyclo-hexane-1,4-diamine (18).
Following the general procedure, and using trans-1,4-diaminocyclohexane (45 mg, 0.4 mmol), compound 18 was obtained as yellow solid (0.08 g, 80%) mp = 260–263 °C; 1H NMR (DMSO-d6) δ: 8.05 (d, J = 8.4 Hz, 2H), 7.93 (brs, 1H), 7.83 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.40 (t, J = 6.8 Hz, 1H), 3.80–3.78 (m, 2H), 2.69 (s, 3H), 2.05–2.03 (m, 4H), 1.91–1.85 (m, 4H), 1.28 (brs, 2H); MS (m/z) 431; HRMS (EI) m/z 431.1780 M+, calcd for C24H25N5OS 431.1780; Anal. Calc. for: (C24H25N5OS): C, 66.80; H, 5.84; N, 16.23%; Found: C, 66.80; H, 5.84; N, 16.23%.
4.1.14. 2-{[5-(2-((1,1’-Biphenyl)-4-yl)-4-methylthiazol-5-yl)-1,3,4-oxadiazol-2-yl]amino} ethan-1-ol (19).
Following the general procedure, and using 2-aminoethan-1-ol (21 μL, 0.4 mmol), compound 19 was obtained as yellow solid (0.06 g, 65%) mp = 210–213 °C; 1H NMR (DMSO-d6) δ: 8.06 (d, J = 8.4 Hz, 2H), 7.90 (brs, 1H), 7.83 (d, J = 8.4 Hz, 2H), 7.73 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.41 (t, J = 6.8 Hz, 1H), 4.78 (brs, 1H), 3.58–3.53 (m, 2H), 3.38–3.35 (m, 2H), 2.68 (s, 3H); MS (m/z) 378; HRMS (EI) m/z 378.1150 M+, calcd for C20H18N4O2S 378.1150; Anal. Calc. for: (C20H18N4O2S): C, 63.47; H, 4.79; N, 14.80%; Found: C, 63.47; H, 4.79; N, 14.80%.
4.1.15. (S)-{1-[5-(2-((1,1’-Biphenyl)-4-yl)-4-methylthiazol-5-yl)-1,3,4-oxadiazol-2-yl]pyro-lidin-2-yl}methanol (20).
Following the general procedure, and using (S)-(+)-2-pyrrolidinemethanol (40 μL, 0.4 mmol), compound 20 was obtained as yellow solid (0.06 g, 61%) mp = 174–175 °C; 1H NMR (DMSO-d6) δ: 8.06 (d, J = 8.4 Hz, 2H), 7.83 (d, J = 8.4 Hz, 2H), 7.76 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.41 (t, J = 6.8 Hz, 1H), 4.88 (brs, 1H), 3.93–3.90 (m, 1H), 3.55–3.48 (m, 2H), 3.43–3.41 (m, 2H), 2.70 (s, 3H), 2.05–1.90 (m, 4H); MS (m/z) 418; HRMS (EI) m/z 418.1463 M+, calcd for C23H22N4O2S 418.1463; Anal. Calc. for: (C23H22N4O2S): C, 66.01; H, 5.30; N, 13.39%; Found: C, 66.01; H, 5.30; N, 13.39%.
4.1.16. (R)-{1-[5-(2-((1,1’-Biphenyl)-4-yl)-4-methylthiazol-5-yl)-1,3,4-oxadiazol-2-yl]pyro-lidin-2-yl}tmethanol (21).
Following the general procedure, and using (R)-(-)-2-pyrrolidinemethanol (40 μL, 0.4 mmol), compound 21 was obtained as yellow solid (0.07 g, 69%) mp = 230–231 °C; 1H NMR (DMSO-d6) δ: 8.06 (d, J = 8.4 Hz, 2H), 7.83 (d, J = 8.4 Hz, 2H), 7.76 (d, J = 7.2 Hz, 2H), 7.53 (t, J = 7.6 Hz, 2H), 7.41 (t, J = 6.8 Hz, 1H), 4.85 (brs, 1H), 3.93–3.90 (m, 1H), 3.60–3.58 (m, 2H), 3.38–3.36 (m, 2H), 2.70 (s, 3H), 2.08–1.92 (m, 4H); MS (m/z) 418; HRMS (EI) m/z 418.1463 M+, calcd for C23H22N4O2S 418.1463; Anal. Calc. for: (C23H22N4O2S): C, 66.01; H, 5.30; N, 13.39%; Found: C, 66.01; H, 5.30; N, 13.39%.
4.2. Microbial strains, cell lines and culture media
The bacterial and fungal strains (S2 Table in S1 File) used in this study were clinical isolates obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), the Centers for Disease Control and Prevention (CDC) and Biodefense and Emerging Infections Research Resources Repository (BEI Resources) (Manassas, VA, USA). RPMI 1640 (Thermo Fisher Scientific, Waltham, MA), YPD broth, YPD agar, cation adjusted Mueller-Hinton broth, brain heart infusion broth, and lactobacilli MRS broth (Becton, Dickinson and Company, Franklin Lakes, NJ) were purchased from commercial vendors. Phosphate buffered saline was purchased from Fisher Scientific (Waltham, MA). Yeast extract, L-cysteine, vitamin K, 3-(N-Morpholino)propanesulfonic acid (MOPS) and hemin were obtained from Sigma-Aldrich (St. Louis, MO). Human colorectal adenocarcinoma epithelial cells (Caco-2) (ATCC HTB-37), and monkey kidney epithelial cells (Vero) (ATCC CCL-81-VHG) were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA).
4.2.1. Initial screening of the bisphenylthiazoles against Gram-positive and Gram-negative bacteria.
The minimum inhibitory concentrations (MICs) of the tested compounds and control drugs against clinically-relevant bacterial strains were determined using the broth microdilution method, according to guidelines outlined by the Clinical and Laboratory Standards Institute (CLSI) [43], or as described previously [10].
4.2.2. Determination of the minimum inhibitory concentration (MIC) of bisphenylthiazoles against a panel of Candida, Cryptococcus and Aspergillus strains and determination of the minimum fungicidal concentration (MFC).
Serial dilutions (from 128 μg/mL to 0.06 μg/mL) of the tested compounds and control drugs (fluconazole, itraconazole and amphotericin) (in triplicates), were screened against clinical isolates of Candida albicans, Candida auris, Candida glabrata, Candida parapsilosis, Candida tropicalis, Candida krusei, Cryptococcus neoformans, Cryptococcus gattii and Aspergillus fumigatus species using the broth microdilution method according to the Clinical and Laboratory Standards Institute guidelines [44]. MICs were determined as the lowest concentration of the compounds that inhibited the fungal growth by 50% after incubation at 35 °C for 24 h (for Candida and Aspergillus), or 48 h (for Cryptococcus). The minimum fungicidal concentration (MFC) of these compounds was tested by plating 4 μL from wells with no growth onto YPD agar plates. The plates were incubated at 37 ºC for 24 hours before recording the MFC, which was categorized as the lowest concentration that reduced fungal growth by 99.9% [45]. The experiment was repeated three independent times.
4.2.3. Safety profile assessment of bisphenylthiazoles in Caco-2 and Vero cells.
To explore the tolerability of bisphenylthiazoles, their cytotoxicity profile was assessed in human colorectal adenocarcinoma (Caco-2) and monkey kidney epithelial cells (Vero) as described earlier [8, 46–48]. Briefly, compounds were incubated with the cells for 24 hours. Then, cells were incubated with MTS reagent for 3 hours before measuring the absorbance values (OD490). The experiment was repeated in two independent times.
4.2.4. In vitro antimicrobial evaluation of bisphenylthiazoles against normal human microflora.
Broth microdilution was utilized to determine the activity of bisphenylthiazoles against the human gut microflora as described elsewhere [49, 50]. A bacterial solution equivalent to 0.5 McFarland standards was prepared and diluted in MRS broth to achieve a bacterial concentration of approximately 5 x 105 CFU/mL. Then, compounds/control antifungals (in triplicates), were added to the plates and serially diluted with media containing bacteria. The plates were incubated for 48 hours at 37 °C before recording the MIC values. The experiment was repeated three independent times.
4.2.5. Evaluation of synergistic interactions using a checkerboard assay.
To evaluate the interactions between bisphenylthiazoles and the standard antifungal agents (fluconazole, amphotericin B, 5-fluorocytosine and caspofungin) against 2 C. auris clinical isolates, a standard checkerboard assay was utilized as described in previous studies [51–53]. The fractional inhibitory concentration index (FICI) was calculated for each interaction. Interactions where the FICI was ≤0.5 were categorized as synergistic (SYN). FICI values of >0.5–1.25 were categorized as additive (ADD). FICI values of >1.25–4 were categorized as indifferent, and FICI values of > 4 were categorized as antagonistic [54]. The experiment was repeated three independent times.
Supporting information
S1 File. 1H and 13C NMR spectra of all new described compounds, description of strains used in this study, toxicity data for amphotericin B against Vero cells, and MICs and FICI values obtained in the checkerboard assay.
https://doi.org/10.1371/journal.pone.0258465.s001
(PDF)
References
- 1. Sinkó J, Sulyok M, Denning DW. Burden of serious fungal diseases in Hungary. Mycoses. 2015;58:29–33. pmid:26449504
- 2. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Science translational medicine. 2012;4(165):165rv13–rv13. pmid:23253612
- 3. Berkow EL, Lockhart SR. Fluconazole resistance in Candida species: a current perspective. Infection and drug resistance. 2017;10:237. pmid:28814889
- 4. Fu J, Ding Y, Wei B, Wang L, Xu S, Qin P, et al. Epidemiology of Candida albicans and non-C. albicans of neonatal candidemia at a tertiary care hospital in western China. BMC infectious diseases. 2017;17(1):1–6.
- 5. Flevari A, Theodorakopoulou M, Velegraki A, Armaganidis A, Dimopoulos G. Treatment of invasive candidiasis in the elderly: a review. Clinical interventions in aging. 2013;8:1199. pmid:24043935
- 6. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873–81. pmid:28483415.
- 7. Chen Y-C, Chang T-Y, Liu J-W, Chen F-J, Chien C-C, Lee C-H, et al. Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study. BMC infectious diseases. 2015;15(1):277. pmid:26194004
- 8. Hammad A, Abutaleb NS, Elsebaei M, Norvil AB, Alswah M, Ali AO, et al. From Phenylthiazoles to Phenylpyrazoles: Broadening the Antibacterial Spectrum towards Carbapenem-Resistant Bacteria. Journal of medicinal chemistry. 2019.
- 9. Elsebaei MM, Mohammad H, Samir A, Abutaleb NS, Norvil AB, Michie AR, et al. Lipophilic efficient phenylthiazoles with potent undecaprenyl pyrophosphatase inhibitory activity. European journal of medicinal chemistry. 2019;175:49–62. pmid:31075608
- 10. AbdelKhalek A, Abutaleb NS, Mohammad H, Seleem MN. Antibacterial and antivirulence activities of auranofin against Clostridium difficile. Int J Antimicrob Ag. 2019;53(1):54–62. pmid:30273668
- 11. Hagras M, Abutaleb NS, Ali AO, Abdel-Aleem JA, Elsebaei MM, Seleem MN, et al. Naphthylthiazoles: targeting multidrug-resistant and intracellular Staphylococcus aureus with biofilm disruption activity. ACS infectious diseases. 2018;4(12):1679–91. pmid:30247876
- 12. Tomasi A, Albano E, Botti B, Vannini V. Detection of free radical intermediates in the oxidative metabolism of carcinogenic hydrazine derivatives. Toxicol Pathol. 1987;15(2):178–83. pmid:3039646.
- 13. Nelson SD, Mitchell JR, Snodgrass WR, Timbrell JA. Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. The Journal of pharmacology and experimental therapeutics. 1978;206(3):574–85. Epub 1978/09/01. pmid:702322.
- 14. Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. The Journal of pharmacology and experimental therapeutics. 1980;213(2):364–9. Epub 1980/05/01. pmid:6767840.
- 15. Rolla AR. Letter: Isoniazid hepatoxicity. Annals of internal medicine. 1974;80(2):278–9. Epub 1974/02/01. pmid:4811806.
- 16. Belkaid Y, Hand TW. Role of the Microbiota in Immunity and Inflammation. Cell. 2014;157(1):121–41. pmid:24679531
- 17. Berkow EL, Lockhart SR. Fluconazole resistance in Candida species: a current perspective. Infection and drug resistance. 2017;10:237–45. pmid:28814889
- 18. Kauffman CA. Candiduria. Clinical Infectious Diseases. 2005;41(Supplement_6):S371–S6. pmid:16108001
- 19. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clinical microbiology reviews. 1999;12(1):80–96. pmid:9880475
- 20. Hernando-Ortiz A, Mateo E, Ortega-Riveros M, De-la-Pinta I, Quindós G, Eraso E. Caenorhabditis elegans as a model system to assess Candida glabrata, Candida nivariensis, and Candida bracarensis Virulence and Antifungal Efficacy. Antimicrob Agents Ch. 2020;64(10):e00824–20.
- 21. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clinical microbiology reviews. 2010;23(2):253–73. pmid:20375352
- 22.
Vallabhaneni S, Cleveland AA, Farley MM, Harrison LH, Schaffner W, Beldavs ZG, et al., editors. Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008–2014. Open forum infectious diseases; 2015: Oxford University Press.
- 23. Pfaller MA, Rhomberg PR, Messer SA, Jones RN, Castanheira M. Isavuconazole, micafungin, and 8 comparator antifungal agents’ susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagnostic Microbiology and Infectious Disease. 2015;82(4):303–13. pmid:25986029
- 24. Irfan M, Alam S, Manzoor N, Abid M. Effect of quinoline based 1,2,3-triazole and its structural analogues on growth and virulence attributes of Candida albicans. PLOS ONE. 2017;12(4):e0175710. pmid:28430797
- 25. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41–4. pmid:19161556
- 26. Belkin A, Gazit Z, Keller N, Ben-Ami R, Wieder-Finesod A, Novikov A, et al. Candida auris infection leading to nosocomial transmission, Israel, 2017. Emerging infectious diseases. 2018;24(4):801. pmid:29553329
- 27. Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLOS pathogens. 2017;13(5):e1006290. pmid:28542486
- 28. Hager CL, Larkin EL, Long L, Abidi FZ, Shaw KJ, Ghannoum MA. In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris. Antimicrob Agents Ch. 2018;62(3). ARTN e02319–17 pmid:29311065
- 29. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, et al. Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus—United States, May 2013-August 2016. Mmwr-Morbid Mortal W. 2016;65(44):1234–7. pmid:27832049
- 30. Kumar D, Banerjee T, Pratap CB, Tilak R. Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis. J Infect Dev Countr. 2015;9(4):435–7. pmid:25881537
- 31. Sharma C, Singh A, Singh PK, Prakash A, Meis JF, Chowdhary A. Genotyping of multidrug resistant Indian Candida auris isolates by Multi Locus Sequence Typing, Amplified Fragment Length Polymorphism and MALDI-TOF-MS and their antifungal susceptibility profile. Mycoses. 2015;58:119–20.
- 32. Sarma S, Kumar N, Sharma S, Govil D, Ali T, Mehta Y, et al. Candidemia caused by amphotericin B and Fluconazole resistant Candida auris. Indian J Med Microbi. 2013;31(1):90–U133. pmid:23508441
- 33. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007–2009. Emerging infectious diseases. 2011;17(10):1846. pmid:22000354
- 34. Lewis RE. Current Concepts in Antifungal Pharmacology. Mayo Clin Proc. 2011;86(8):805–17. pmid:21803962
- 35. Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017;16(9):603–16. pmid:28496146
- 36. Kagan S, Ickowicz D, Shmuel M, Altschuler Y, Sionov E, Pitusi M, et al. Toxicity mechanisms of amphotericin B and its neutralization by conjugation with arabinogalactan. Antimicrob Agents Ch. 2012;56(11):5603–11. pmid:22908154
- 37. França FD, Tagliati CA, Ferreira A, Chaves MM. Amphotericin B nephrotoxicity in vitro: Differential profile of PKC signaling in VERO and MDCK cell lines. Drugs. 2013;5(4):10.
- 38. Lincopan N, Mamizuka EM, Carmona-Ribeiro AM. Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments. Journal of Antimicrobial Chemotherapy. 2005;55(5):727–34. pmid:15761070
- 39. Rybak MJ, McGrath BJ. Combination antimicrobial therapy for bacterial infections—Guidelines for the clinician. Drugs. 1996;52(3):390–405. pmid:8875129
- 40. Sanders CV, Aldridge KE. Antimicrobial Therapy of Anaerobic Infections, 1991. Pharmacotherapy. 1991;11(2):S72–S9. pmid:2041835
- 41. Johnson MD, Perfect JR. Use of Antifungal Combination Therapy: Agents, Order, and Timing. Curr Fungal Infect R. 2010;4(2):87–95. pmid:20574543
- 42. Hagras M, Hegazy YA, Elkabbany AH, Mohammad H, Ghiaty A, Abdelghany TM, et al. Biphenylthiazole antibiotics with an oxadiazole linker: An approach to improve physicochemical properties and oral bioavailability. European journal of medicinal chemistry. 2018;143:1448–56. pmid:29126738
- 43.
Clinical and Laboratory Standards Institute, CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Wayne, PA: 2012.
- 44.
Clinical and Laboratory Standards Institute C. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard—Third Edition, Wayne, PA,. 2008;M27–A3
- 45. Canton E, Peman J, Viudes A, Quindos G, Gobernado M, Espinel-Ingroff A. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagnostic Microbiology and Infectious Disease. 2003;45(3):203–6. pmid:12663162
- 46. Kotb A, Abutaleb NS, Seleem MA, Hagras M, Mohammad H, Bayoumi A, et al. Phenylthiazoles with tert-Butyl side chain: Metabolically stable with anti-biofilm activity. European Journal of Medicinal Chemistry. 2018;151:110–20. pmid:29605807
- 47. Opoku-Temeng C, Naclerio GA, Mohammad H, Dayal N, Abutaleb NS, Seleem MN, et al. N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria. European Journal of Medicinal Chemistry. 2018;155:797–805. pmid:29957525
- 48. Seleem MA, Disouky AM, Mohammad H, Abdelghany TM, Mancy AS, Bayoumi SA, et al. Second-generation phenylthiazole antibiotics with enhanced pharmacokinetic properties. Journal of medicinal chemistry. 2016;59(10):4900–12. pmid:27187739
- 49. Kushiro A, Chervaux C, Cools-Portier S, Perony A, Legrain-Raspaud S, Obis D, et al. Antimicrobial susceptibility testing of lactic acid bacteria and bifidobacteria by broth microdilution method and Etest. International journal of food microbiology. 2009;132(1):54–8. Epub 2009/04/14. pmid:19361877.
- 50.
CLSI calsi. Methods for Dilution Antimicrobial Susceptibility tests for bacteria that Grow Aerobically. Approved Standard—9th edition. 2012;M07–A9.
- 51. MartinezIrujo JJ, Villahermosa ML, Alberdi E, Santiago E. A checkerboard method to evaluate interactions between drugs. Biochemical pharmacology. 1996;51(5):635–44. pmid:8615900
- 52. Mohammad H, Cushman M, Seleem MN. Antibacterial Evaluation of Synthetic Thiazole Compounds In Vitro and In Vivo in a Methicillin-Resistant Staphylococcus aureus (MRSA) Skin Infection Mouse Model. Plos One. 2015;10(11). ARTN e0142321 pmid:26536129
- 53. Eldesouky HE, Li XY, Abutaleb NS, Mohammad H, Seleem MN. Synergistic interactions of sulfamethoxazole and azole antifungal drugs against emerging multidrug-resistant Candida auris. International Journal of Antimicrobial Agents. 2018;52(6):754–61. pmid:30145250
- 54. Meletiadis J, Pournaras S, Roilides E, Walsh TJ. Defining Fractional Inhibitory Concentration Index Cutoffs for Additive Interactions Based on Self-Drug Additive Combinations, Monte Carlo Simulation Analysis, and In Vitro-In Vivo Correlation Data for Antifungal Drug Combinations against Aspergillus fumigatus. Antimicrob Agents Ch. 2010;54(2):602–9. pmid:19995928